New
Advancing Patient Care: VRF Backs Transformative Dermatology Research
We proudly support Dr. John Barbieri's proposal, "Incorporating Patient Preferences into Health Outcome Assessment for Economic Evaluation in Chronic Skin Disease: The Skindex-Utility Index." This project aims to develop a specialized health utility measure for dermatology, with a focus on vitiligo therapies' impact on patients' well-being. Stay tuned for updates as we advance patient care through this transformative research.
FAQOther Questions
- Is it Bitiligo? Vitaligo? Veteligo?
There are so many different ways that people try and spell or even pronounce Vitiligo. Here are some common mis-spellings: bitiligo, vitigo, vitaligo, vitilago, vitiglio, vitag...
- Why Does the IRS Still Show an Old Revocation for VR Foundation?
IRS Status · A Short FAQ The old entry records the past. Publication 78 shows where VR Foundation stands today. Updated August 2026 · EIN 45-2498489 Tax records are rarely elega...
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.